Join the Society for FREE Today!
SOHO is a global society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO’s mission is to expedite worldwide research and education through the exchange of scientific information.
SOHO represents physicians and other professionals from all corners of the world. SOHO is leading vital efforts to further treatments for those with hematologic malignancies.
Become a SOHO Member free-of-charge. Join us and experience the benefits of membership.
The Society of Hematologic Oncology (SOHO) holds its annual meeting during the September timeframe of each year in Houston, Texas. Note that SOHO members receive a 40% discount on registration fees. The twelfth annual meeting of the Society of Hematologic Oncology (SOHO 2024) is scheduled for September 4-7, 2024 at the GRB Convention Center in Houston, Texas. As a hybrid event, SOHO 2024 offers in-person, virtual and on-demand participation.
The Ambassador Program was created to increase geographical diversity and promote international understanding among hematologic oncology experts around the world. If you are interested, Contact us!
The incidence of bleeding events in patients with CLL receiving BTKis is 26.6 per 100 patients per year, according to a study presented at the 2024 American Society of Clinical Oncology Annual Meeting.
MPN depend on mutated JAK signaling, and targeting the mutations suppressed disease features and improved overall survival.
Pelabresib plus ruxolitinib improved spleen and symptom responses in JAKi-naïve patients with myelofibrosis.
The approval was based on efficacy and safety results of the randomized, placebo-controlled IMerge study.
Treatment with luspatercept improved transfusion burden and anemia across four cohorts of patients with myelofibrosis.
An expert panel convened at the "HemOnc Pulse" Live meeting in Chicago explores unanswered questions in DLBCL management.
The panel discussed ALL treatment, associated toxicities, and the possibility of a chemotherapy-free approach.
"Very interesting and exciting to share ideas and data with other hem/onc clinicians and scientists from around the world" –Prof. Dieter Hoelzer, founding member
